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Introduction: A clinically useful diagnostic classifi-
cation should identify most patients who are treated. To 
our surprise, DSM-IV criteria for major depressive episodes 
(MDE) detected fewer than 50% of a community sample (the 
Zurich study) who had received treatment for depression.1 
Treated subjects often experience episodes lasting under 2 
weeks, or with fewer symptoms than required for a DSM 
diagnosis. 
Methods: Our paper focuses on the validity and clinical 
relevance of the length of depressive syndromes, defined by 
the presence of 5 or more of 9 diagnostic symptoms (DSM-IV). 
Results: We found depressive syndromes lasting under 
2 weeks to be highly prevalent, and those lasting 4+ days to 
have equal validity (family history, age of onset, course) and 
treatment rates to episodes of 2-4 weeks. 
Conclusions: The 2-week criterion for MDE would 
appear questionable. Our results need confirmation by larger 
epidemiological studies.
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¿Son dos semanas, el criterio de la duración 
óptima de la depresión mayor?
Introdución: Una clasificación diagnóstica de utilidad 
clínica debe identificar la mayoría de los pacientes que son 
tratados. Para nuestra sorpresa, los criterios del DSM-IV para 
el trastorno depresivo mayor (TDM) detectaron menos de 
50% de una muestra de la comunidad (el estudio de Zurich) 
que habían recibido tratamiento para depresión. Los suje-
tos tratados experimentan a menudo episodios que duran 
menos de 2 semanas, o presentan menos síntomas de los 
requeridos para un diagnóstico de TDM.  
Método: Nuestro documento se centra en la validez y la 
relevancia clínica de la duración de los síndromes depresivos, 
que se define por la presencia de 5 o más de los 9 síntomas 
de diagnóstico (DSM-IV). 
Resultados: Encontramos síndromes depresivos que du-
ran menos de 2 semanas que eran altamente prevalentes y 
algunos que duran 4 + días tienen la misma validez (ante-
cedentes familiares, la edad de inicio, curso) y las tasas de 
tratamiento de los episodios de 2-4 semanas. 
Conclusiones: El criterio de 2 semanas para TDM parece 
cuestionable. Nuestros resultados necesitan ser confirmados 
por estudios epidemiológicos más amplios. 
Palabras clave: Episodio depresivo mayor, Criterios diagnósticos, Duración mínima, Validez 
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IntRoduCtIon
Episode duration is often a basic criterion of psychiatric 
diagnoses. There are doubts whether the current definitions 
are valid and clinically meaningful in this respect, in the 
sense that they characterise as many treated patients in the 
community as possible. The scale of this problem is illustrated 
by the definition of generalised anxiety disorder (GAD). The 
minimum episode length for a diagnosis of GAD has 
fluctuated over the years in the DSM system: it was 1 month 
in DSM-III, 3 months in DSM-III-R, 6 months in DSM-IV and 
is back to 3 months in DSM-5. 
For depression the situation is clear: we use an 
uncontested minimum duration of 2 weeks for the definition 
of a major depressive episode in both DSM and ICD, although 
this definition, too, covers just under half of the patients 
treated for any kind of depression.1 Our earlier analysis 
demonstrated that (a) subjective suffering/distress and (b) 
work impairment are the factors most closely associated 
with treatment seeking for many syndromes.
This paper tests the 2 weeks’ duration criterion for 
depression on the basis of epidemiological data on various 
episode durations by means of important variables reflecting 
validity and clinical relevance. We focus on the clinical 
relevance of shorter episodes of depression, for instance 4+ 
days compared to 2 weeks. We will also present some data 
on treatment seeking. 
MethodS
Sampling and procedure
The Zurich Study comprised a cohort of 4547 subjects 
(m=2201; f=2346) representative of the canton of Zurich in 
Switzerland. Participants were screened with the Symptom 
Checklist 90-R2 in 1978, when the men were 19 and the 
women 20 years old. Male and female participants were 
sampled using different approaches. For the men, this was 
based on the army screening test which all Swiss males 
undergo at the age of 19. Conscripts within a given 
catchment area thus comprise its complete male age group. 
With the consent of the military authorities, but 
independently of their procedure, we randomly screened all 
male conscripts in the canton of Zurich in this age group. 
The refusal rate was 0.3%. For the women, sampling was 
based on the complete electoral register of the canton of 
Zurich. 50% of the female participants were randomly 
selected and received questionnaires by mail; 75% 
responded. 
In order to increase the probability of the development 
of psychiatric syndromes, a stratified subsample of 591 
subjects (292 males, 299 females) was then selected for 
Figure 1              Design of the Zurich Study
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interview, with two-thirds consisting of high scorers (defined 
by the 85th percentile or more on the global severity index 
(GSI) of the SCL-90-R, the other third being a random 
sample of probands with scores below the 85th percentile. 
Such a two-phase procedure, consisting of initial screening 
and subsequent interview with a stratified subsample, is 
fairly common in epidemiological research.3 
Interviews were conducted with the “Structured 
Psychopathological Interview and Rating of the Social Con-
sequences of Psychological Disturbances for Epidemiology” 
(SPIKE),4 administered by specially trained clinical psycholo-
gists and psychiatrists. This semi-structured interview, speci-
fically developed for epidemiological surveys in psychiatric 
research, assesses data on socio-demography, somatic syn-
dromes, psychopathology, substance use, medication, health 
services, impairment, and social activity. Its reliability and 
validity have been reported previously.5
Altogether seven interview waves have been conducted: 
in 1979, 1981, 1986, 1988, 1993, 1999, and 2008 (see Figure 
1). An analysis conducted in 1999 showed that the initial 
allocation to the two groups, above and below the 85th 
percentile of the GSI, did not change over time, although 
dropouts tended to be among the extremely high or low 
scorers on the GSI.6 We repeated the attrition analyses for 
the last interview in 2008, and found, in addition, that the 
participants who left the study did not differ significantly 
from those who remained with regard to socio-economic 
status and education level at outset of the study. Nor was 
there a difference in their initial psychopathologic 
impairment according to the nine SCL-90-R subscales. 
However, there was a moderate sex bias: more males dropped 
out (OR=1.82; 95%-CI=1.31-2.53). 
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definition and assessment of depressive 
syndromes 
For the purposes of our analysis, the syndrome of 
depression was defined by the presence of any depressive 
episode (regardless of duration) with 5 or more of 9 
diagnostic symptoms according to DSM-IV and ICD-10. 
Consequences (distress, impairment) were not included in 
the definition.
The data collected across the seven interviews varied in 
parallel with the revisions of the DSM. Thus, for depression, 
the number of depressive symptoms (including suicidality) 
assessed was 9 in 1979, 12 in 1981, 28 in 1986, 33 in 1988, 
33 in 1993, 34 in 1999, and 39 in 2008; the assessment was 
routinely followed by a final open question about other 
symptoms.
For the definition of depressive syndromes we added, in 
1979 and 1981, the data from the self-assessment symptom 
checklist (SCL-90-R), which contains 13 items of depression 
present over the last four weeks.2
In all 7 interviews, data were collected on treatment 
seeking and work impairment over the previous twelve 
months. Distress was regularly assessed using visual analogue 
scales from 0 to 100; in addition, in the last 4 interviews the 
degree of work impairment was assessed in the same way.
The duration of depressive episodes was classified by 
length: 3 months, 1 month, 2 weeks, 4 or more days, and 1-3 
days. In order to increase the statistical power of the present 
analyses, the diagnostic variable used does not take into 
account the episode duration at each point of measurement, 
but instead is defined cumulatively, i.e. it is the highest score 
over the period of a subject’s participation. Thus, for a 
participant in only two assessment waves, we considered the 
longer of the two reported durations. All episodes occurred 
during the year prior to the interviews.
The interview did not assess the lifetime occurrence of 
episodes but the treatment of depression over lifetime. 
Those subjects who had been treated for depression over 
lifetime but had had no manifestations of depressive 
episodes in any of the seven interview years constituted a 
special group.
Treatment was defined as treatment by professionals 
(MDs or psychologists).
For the assessment of course we considered the annual 
occurrence both of depressive symptoms and of treatment 
for depression for all 30 years of observation and computed 
the intra-individual percentage of years in which subjects 
were symptomatic or treated.
Participants’ personality traits were assessed by the 
Freiburg Personality Inventory,7 the General Behaviour 
Inventory,8 and an interview question whether they had 
been more anxious than their peers at school age. Coping 
(mastery, self-esteem) was assessed by the instrument 
developed by Pearlin and Schooler.9
Statistics
First we conducted a series of cross-sectional analyses. 
Non-parametric methods (χ2-tests for categorical and 
Kruskal-Wallis tests for continuous variables) were applied 
for overall group comparisons and a series of generalised 
linear models (GLMs) for specific associations of 4+ days’ vs. 
2 weeks’ duration. In all GLMs, the duration of the depression 
syndrome was entered as the dependent variable and various 
clinical characteristics as predictor variables. A robust 
estimator was applied to reduce effects of outliers and 
influential observations. 
For longitudinal analyses of associations between 
treatment use and clinical characteristics we computed a 
series of generalised estimating equations (GEEs). These 
analyses were introduced to fit regression models that 
account for within-subject correlation, an inherent element 
of longitudinal studies that rely on repeated measures. GEEs 
allow one to specify the working correlation matrix and to 
fit the distribution and the link-function. Owing to the 
dichotomous dependent variables, a binomial distribution 
with logit link-function best fitted our data. The within-
subject covariance structure was specified with the 
“unstructured” correlation type to avoid having any 
constraints on the covariance structure. Again a robust 
estimator was used and intercept and slope were included in 
the analysis.
Finally, a series of receiver operating characteristic 
(ROC) analyses were conducted to examine which continuous 
predictor variable best discriminated between treatment use 
and non-use. Non-parametric analyses were carried out 
with SAS version 9 for Windows. All other analyses were 
conducted with SPSS version 20 for Macintosh. 
ReSultS
Frequencies and prevalence rates of depressive 
syndromes 
A depressive syndrome defined by the presence of 5+/9 
criterial symptoms of depression was diagnosed at the seven 
interviews, each of which covered the previous twelve 
months; in this first step distress and impairment were not 
taken into account.
A depressive syndrome with a duration of 1-3 days was 
found in 399 of the total sample of 591 subjects; the 
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table 1             depressive syndromes by duration: associations with categorical variables
Group 1:
3 months
Group 2:
1 month
Group 3: 
2 weeks
Group 4:
4 + days
Group 5:
1-3 days
Group 6:
lt trtmt 
depression
Group 7:
others
Significance
N 94 72 42 56 135 25 167 p (1-7) p (1-4)
% % % % % % %
Sex
- Males 35.1 38.9 38.1 51.8 50.4 44 64.1
- Females 64.9 61.1 61.9 48.2 49.6 56 35.9 0.0001 0.24
Prevalence (weighted)
- Males 5.0 10.2 4.5 7.9 20.6 4.1 47.8
- Females 14.0 15.8 5.9 6.7 22.3 4.2 31.1
- M+F 9.6 13.1 5.2 7.3 21.4 4.1 39.3
Treatment prevalence 
weighted
- Depression treatment 
lifetime
6.7 8.6 3.8 3.4 7.5 4.1 0
- Depression treatment 
1979-2008
6.4 7.3 2.4 2.2 3.8 1.1 0
Anxiety treatment 1979-
2008
2.7 3.8 2.6 2.6 2.7 0.6 0.6
Anxiety/panic treatment 
1979-2008
2.9 3.9 2.7 2.6 3.3 1.0 0.6
Family history
- Depression 60.6 66.7 66.7 69.6 48.2 28.0 21.0 0.0001 0.69
- Anxiety 29.0 38.0 43.6 38.9 27.1 26.1 16.4 0.005 0.36
- Anxiety/panic 29.8 37.5 42.9 39.3 27.4 28.0 11.4 0.0001 0.43
- Suicidality 23.4 18.1 23.8 23.2 14.1 4.0 9.0 0.008 0.83
Treatment 1979-2008
- Depression 68.1 50.0 50.0 48.2 28.2 36.0 0 0.0001 0.04
- Anxiety/panic 46.8 38.9 42.9 44.6 24.4 20.0 3.6 0.0001 0.78
Treatment lifetime 
- Depression 75.5 66.7 64.3 66.1 44.4 100 0 0.0001 0.44
- Mania/hypomania 11.7 2.8 2.4 3.6 2.2 0 0 0.0001 0.05
- Anxiety 57.5 47.2 47.6 57.1 34.1 56.0 5.4 0.0001 0.46
- Anxiety/panic 63.8 51.4 50.0 57.1 35.6 56.0 5.4 0.0001 0.32
Suicidality lifetime
- suicide attempts 35.1 19.4 26.2 7.1 10.4 8.0 0.6
- firm suicide plans 41.5 43.1 33.3 57.1 34.1 28.0 16.8
- suicidal ideation 12.8 16.7 19.1 12.5 14.8 4.0 2.4
- none 10.6 20.8 21.4 23.2 40.7 60.0 80.2 0.0001 0.02
Socio-demographic 
variables
- living alone 29.8 26.4 16.7 21.4 20.7 12.0 16.2 0.14 0.37
- always single 34.0 41.7 26.2 44.6 28.9 24.0 51.5 0.0005 0.21
- working full time 46.1 51.6 57.1 59.3 61.3 45.8 81.2 0.0001 0.46
- housewife 8.5 11.1 11.9 8.9 9.6 4.0 6.6 0.83 0.90
22
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table 1             Continuation
weighted cumulative prevalence rate was 56.6%. A 
depressive syndrome lasting at least 4 days was found in 264 
subjects (prevalence 35.2%). The two groups of specific 
interest (groups 3 and 4 in Table 1) were large enough for 
analysis (durations of 4+days N=56 and 2 weeks N=42).
 As expected, depressive syndromes were more common 
among women; the female preponderance grew 
conspicuously as the episode duration increased: while there 
was no clear gender difference in the prevalence rates of the 
shorter depressive syndromes of 1-3 days (F 22.3% vs. M 
20.6%) or of 4-13 days (F 6.7% vs. M 7.9%), there were more 
women in the 2-week (F 5.9% vs. M 4.5%) and 1-month 
groups (F 15.8% vs. M 10.2%); depressive syndromes lasting 
3 months were almost three times more common among 
women than among men (F 14% vs. M 5%).
Across the 30 years of the study the weighted lifetime 
prevalence of treatment was 34.1%: for depressive 
syndromes lasting 2 or more weeks, 19.1%; for syndromes 
shorter than 2 weeks, 10.9%; a further 4.1% subjects did not 
report any depression during the interview years but had 
been treated at least once over their lifetime.
Restricted to the period covered by the interviews 
(1979-2008) the treatment prevalence was 22.3%.
diagnostic validity of the length of depression
The focus of this paper is the optimum length of a 
depressive episode in terms of validators and treatment. 
Table 1 presents the categorical data and table 2 the 
continuous variables. We computed the significances across 
all sub-groups but concentrate here on the differences 
between the first four groups: depression lasting 3 months, 
1 month, 2 weeks and 4+ days.  Group 5, a large group of 
153 subjects with episodes lasting 1-3 days, is not relevant 
in this context since we do not focus on recurrence (recurrent 
brief depression). 
Our four analysis groups did not differ significantly 
from each other with regard to a positive family history 
(FH+) of depression, suicidality, anxiety or anxiety/panic. But 
they all differed clearly from the 173 subjects with no 
depression. 
As stated earlier, the data on treatment (yes/no) was 
computed in two ways 1) treatment during the 12 months 
prior to the interviews, and 2) lifetime treatment. The four 
groups did not differ in treatment rates for depression or 
anxiety/panic in either computing method. More especially, 
the treatment rates for depression of the subjects with 
depressive syndromes lasting 4+ days (48.2%) did not differ 
statistically from those with episodes of 2 weeks’ duration 
(50.0%). Nor did those two groups differ statistically 
regarding the percentage of years in treatment over the 
period of 30 years 
Suicidality over lifetime differed significantly among 
the four groups. Suicide attempt rates were highest among 
subjects with 3-month depressive syndromes (35.1%) and 
lowest in those with depressive syndromes lasting 4+ days 
(7.1%). Similar significant differences between the groups 
were found for an anxious temperament, but not for a 
cyclothymic temperament or a depressive personality type/
temperament. 
Marital status
- single 34.0 41.7 23.8 44.6 28.9 24.0 51.5
- married 36.2 41.7 50.0 33.9 48.9 56.0 38.3
- sep./divcd/widowed 29.8 16.7 26.2 21.4 22.2 20.0 10.2 0.0008 0.35
School education 
- basic 38.7 23.5 27.5 25.0 35.3 32.0 44.9
- secondary 35.5 47.1 35.0 34.6 33.8 40.0 34.0
- upper secondary 25.8 29.4 37.5 40.4 30.8 28.0 21.2 0.09 0.21
Temperament
- Anxious 29.8 14.3 10.6 8.6 28.0 9.7 10.8 0.0001 0.02
- Cyclothymic 38.5 32.1 25.8 28.6 26.0 16.1 16.9 0.0001 0.37
- Depressed (PDD.GBI2x) 18.6 12.9 11.4 26.0 14.8 4.7 1.2 0.002 0.23
Group 1:
3 months
Group 2:
1 month
Group 3: 
2 weeks
Group 4:
4 + days
Group 5:
1-3 days
Group 6:
lt trtmt 
depression
Group 7:
others
Significance
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Of great clinical importance are subjective suffering/
distress and work impairment, which we measured on a scale 
from 0-100 (Table 2). Subjects with 3-month or 1-month 
depression scored higher (means of 87 and 85) than those 
with 2-week or 4+-day depression; but the last two groups 
still scored relatively high, with equal means around 76 on 
the scale from 0-100. The degree of work impairment varied 
significantly but unsystematically between means of 40 to 
55. Similar unsystematic variations were found for 
neuroticism, coping, self-esteem and the severity of the 
symptoms self-assessed by the SCL-90-R between 1978 and 
2008. No significant differences were found among the four 
episode duration groups (1-4) as regards the age at onset of 
depression and anxiety or the personality traits of 
extraversion and aggression.
two-week compared to four-day depression
The discrimination between depressive syndromes 
lasting 4+ days and those lasting 2 weeks using generalised 
linear models is reported in Table 3. A duration of 4+-days 
served as the reference. In the bivariate analyses none of the 
variables included discriminated significantly between the 
4+ days’ and 2 weeks’ durations, although the odds ratios 
for the frequency of symptoms were substantial. In a larger 
sample those associations might have reached statistical 
significance. In view of the small sample, no multivariate 
analysis was carried out. 
Variables associated with treatment seeking
Clinically speaking, a good case definition should cover 
as many treated patients as possible. The distinction of 
2 weeks’ vs. 4 days’ depression resulted in a sensitivity of 
0.62 vs. 0.76 and a specificity of 0.78 vs. 0.71 for treatment 
seeking.
We also used GEEs to examine longitudinally nine 
further variables as predictors of treatment seeking for 
depression.
The bivariate associations are reported in Table 4. All 
variables included were statistically significant. Strong 
associations were found for the number of criterial 
depressive symptoms, suffering/distress, and suicidality. The 
table 2             depressive syndromes by duration: associations with continuous variables
Group 1:
3 months
Group 2:
1 month
Group 3:
 2 weeks
Group 4:
4 + days
Group 5:
1-3 days
Group 6:
lt trtmt 
depression
Group 7:
others
Significance
n 94 72 42 56 135 25 167 p (1-7) p (1-4)
m dS m dS m dS m dS m dS m dS m dS
Age at onset
- Depression 15.8 7.2 14.8 4.7 15.2 5.5 15.1 5.2 16.4 5.9 20.3 9.4 17.7 6.5 0.003 1.0
- Anxiety 18.5 10.5 18.6 11.2 14.9 7.7 16.1 9.2 17.7 9.1 20.8 11.0 17.4 9.4 0.37 0.25
- Anxiety/panic 17.3 10.1 18.1 11.0 13.1 6.5 15.1 8.4 17.7 9.6 20.0 9.9 16.8 9.2 0.15 0.15
- Mania/hypomania 20.9 9.0 23.0 10.8 22.0 9.5 22.3 9.8 22.6 9.4 21.3 14.8 20.1 8.9 0.95 0.96
 Course 1978-2008
- % years symptomatic 53.8 25.6 48.9 26.0 59.3 26.0 56.3 22.3 46.9 26.8 25.3 21.0 22.5 26.4 0.0000 0.18
- % years treated 16.0 19.7 8.8 11.4 12.2 19.9 10.6 15.0 4.4 8.1 8.7 9.1 0 0 0.0000 0.07
Distress (0-100)
-  Depression 1* 87.2 11.7 84.0 15.9 76.3 21.5 75.5 22.7 71.3 25.0 0.0000 0.005
-  Anxiety/panic 68.3 34.7 71.2 32.1 66.0 35.3 64.3 32.6 58.9 35.4 0.08 0.52
Work impairment (0-100)
-  Depression 2* 54.7 28.3 41.0 30.1 51.4 21.2 36.3 28.2 31.0 24.6 0.0000 0.001
-  Anxiety/Panic 42.5 35.2 30.7 34.2 44.4 27.4 34.9 29.1 25.0 30.1 0.004 0.12
FPI 
- Aggression 19.3 7.4 18.0 7.1 17.7 7.5 19.1 6.7 18.1 7.7 15.9 7.8 14.6 6.1 0.002 0.43
- Extraversion 17.5 7.5 18.1 8.0 19.3 7.9 15.4 7.8 18.2 7.8 20.1 7.5 20.8 7.5 0.02 0.15
- Neuroticism 19.8 7.0 16.9 7.0 17.0 5.3 19.2 8.4 16.7 7.0 13.6 4.2 11.8 4.3 0.0000 0.05
1* distress by depression, t-test group 3 vs. 4: p<.60
2* work impairment by depression: group 3 vs. 4: Wilcoxon two-sided, p<.02 
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multivariate analysis confirmed that these variables were 
important, although in an attenuated form (see Table 5). 
distress and work impairment associated with 
treatment seeking
Finally, using ROC analyses, we investigated which item, 
work impairment or general distress (both measured on a 
scale from 0-100), discriminated better between treatment 
seeking and not. 
We conducted separate models for the 4 days’ minimum 
and 2 weeks’ minimum episode durations. In ROC the area 
under the curve (AUC) provides the total discriminatory 
power of a given variable. AUC=1.00 would imply perfect 
discrimination and AUC=0.50 pure chance and thus no 
discriminative power at all. 
The results were as follows. For general distress in ≥4 
days’ depressive episodes: AUC=0.669; for general distress in 
≥2 weeks’ depressive episodes: AUC=0.665; for work 
impairment in ≥4 days’ depressive episodes: AUC=0.627; and 
finally, for ≥2 weeks’ depressive episodes: AUC=0.643. 
In the comparison of ≥4 days’ and 2 weeks’ depression, 
distress was equal but work impairment was significantly 
higher in the latter group.  Comparing treated vs. non-
treated subjects general distress was a slightly better 
discriminator than work impairment. The ROC curve of 
general distress in ≥4 days’ depressive episodes with at least 
5 symptoms is shown in Figure 2. 
dISCuSSIon
To our knowledge this is the first epidemiological study 
to analyse the duration of depressive episodes as a diagnostic 
criterion, in terms of validity, clinical consequences and 
relevance (treatment seeking, distress/suffering and work 
impairment). This paper follows on from an earlier analysis 
in a community sample of the association between certain 
psychiatric syndromes and treatment seeking, which showed 
that DSM-IV diagnostic concepts covered fewer than 50% 
of treated patients.1 In view of the social and clinical 
relevance of treatment seeking, our aim is to contribute to 
improving diagnostic coverage on the basis of replicated 
representative data from countries where treatment is 
available for all.
Before comparing the most interesting of the two groups 
(depressive episodes lasting 2 weeks, and 4 days), we will 
consider all four duration subgroups (3 months, 1 month, 2 
weeks, 4 days). 68% of the 3-month group was treated, and 
about 50% in the other three. As mentioned earlier, the large 
group of 1-3 days’ depression was not taken into account for 
further analyses; its much lower treatment rate (28%) 
introduces the criterion of recurrence, and recurrent brief 
depression is not the subject of this paper.
The validity testing of the four groups showed no 
difference regarding the age at onset of depression, 
percentage of years of being symptomatic for depression, 
family history of depression, lifetime treatment for 
depression, cyclothymic or depressive temperament, or 
personality traits (extraversion, aggression). Unsurprisingly, 
however, the four groups did differ in regard to treatment 
rates during the years covered by the seven interviews, 
suicidality, some personality traits (i.e. anxious temperament 
and neuroticism); the highest scores were routinely found in 
the subjects with 3-month depression (group 1). 
Most important, we found that the two groups of 
greatest interest (episode durations of 2 weeks vs. 4 days) 
table 3              4+ days vs. 2-weeks’ depression, results of a series of generalised linear models (GlMs) 
Predictor oR (95% CI) Wald χ2 (df) Sig
Frequency of depressive episodes over 
the last twelve months
1-3 per year
4-11 per year
Min. 1x per month
Min. weekly
3.18 (0.77; 13.23)
2.18 (0.88; 5.42)
1.15 (0.58; 2.27)
Reference
2.534 (1)
2.831 (1)
0.163 (1)
0.111
0.092
0.687
N of days depressed over the past year 1 SD increase 0.85 (0.60; 1.21) 0.850 (1) 0.357
N of depressive symptoms 1 SD increase 0.95 (0.46; 1.93) 0.023 (1) 0.880
Suffering (0-100) 1 SD increase 1.07 (0.67; 1.72) 0.083 (1) 0.773
Age at onset 1 SD increase 0.81 (0.55; 1.20) 1.075 (1) 0.300
Sex Female
Male
1.24 (0.67; 2.30)
Reference
0.471 (1) 0.493
Suicidality None
Vague
Severe
0.78 (0.36; 1.70)
1.09 (0.55; 2.16)
Reference
0.385 (1)
0.064 (1)
0.535
0.800
Work impairment No
Yes
1.49 (0.50; 4.50)
Reference
0.507 (1) 0.476
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table 5              Results of a Gee: Multivariate associations of treatment seeking in depressed subjects
Predictor oR (95% CI) Wald χ2 (df) Sig
Frequency of symptoms 1-3 per year
4-11 per year
Min. 1x per month
Min. weekly
0,68 (0,45; 1,02)
0,66 (0,40; 1,08)
0,98 (0,62; 1,57)
Reference
3,531 (1)
2,753 (1)
0,006 (1)
0,060
0,097
0,940
N of symptoms 1 SD increase 1,85 (1,39; 2,46) 17,696 (1) 0,000
Maximum duration 1-3 days
Min. 4 days
Min. 2 weeks 
Min. 1 month 
Min. 3 month
0,38 (0,23; 0,61)
0,57 (0,34; 0,98)
0,38 (0,18; 0,79)
0,83 (0,49; 1,40)
Reference
16,060 (1)
4,225 (1)
6,772 (1)
0,503 (1)
0,000
0,040
0,009
0,478
Suffering (0-100) 1 SD increase 1,45 (1,20; 1,76) 14,713 (1) 0,000
Age at onset 1 SD increase 0,93 (0,78; 1,12) 0,524 (1) 0,469
Sex Female
Male
1,51 (1,08; 2,13)
Reference
5,690 (1) 0,017
Suicidality None
Vague
Severe
0,60 (0,40; 0,92)
0,76 (0,51; 1,13)
Reference
5,542 (1)
1,855 (1)
0,019
0,173
Work impairment No
Yes
0,57 (0,41; 0,80)
Reference
10,417 (1) 0,001
table 4              Results of a series of generalised estimating equations (Gees): bivariate associations of treatment-
seeking among patients with depression
Predictor oR (95% CI) Wald χ2 (df) Sig
Frequency of depressive episodes over 
the past twelve months 
1-3 per year
4-11 per year
Min. 1x per month
Min. weekly
0.58 (0.39; 0.86)
0.32 (0.20; 0.53)
0.63 (0.40; 1.00)
Reference
7.371 (1)
19.506 (1)
3.775 (1)
0.007
0.000
0.052
N of days depressed over the past year 1 SD increase 1.63 (1.36; 1.97) 26.584 (1) 0.000
N of depressive symptoms 1 SD increase 3.81 (3.21; 4.51) 239.065 (1) 0.000
Maximum duration of depressive 
episodes
1-3 days
4 days
2 weeks 
1 month 
3 months or more
0.20 (0.13; 0.30)
0.41 (0.25; 0.68)
0.33 (0.18; 0.61)
0.55 (0.34; 0.89)
Reference
51.674 (1)
12.174 (1)
12.475 (1)
6.897 (1)
0.000
0.000
0.000
0.015
Suffering (0-100) 1 SD increase 2.07 (1.75; 2.45) 70.638 (1) 0.000
Age at onset 1 SD increase 0.75 (0.61; 0.91) 8.669 (1) 0.003
Sex Female
Male
2.03 (1.48; 2.80)
Reference
18.822 (1) 0.000
Suicidality None
Vague
Severe
0.13 (0.09; 0.19)
0.66 (0.45; 0.97)
Reference
118.870 (1)
4.512(1)
0.000
0.034
Work impairment No
Yes
0.40 (0.28; 0.55)
Reference
29.171 (1) 0.000
did not differ in regard to family history, age at onset and 
course (percentage of years with depressive symptoms). The 
two groups also showed almost identical treatment rates 
(50% vs. 48.2%), an identical proportion of years treated 
(medians 3.2) and comparable subjective distress/suffering 
(means of 76.3 vs. 75.5). Work impairment as a consequence 
of severity was clearly lower in the 4-day duration group 
(mean 44.4 vs. 34.9), as was the suicide attempt rate (26.2% 
vs. 7.1%). 
Surprisingly also, the more sensitive GLM analyses 
comparing the two critical groups showed no significant 
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differences in sex, age at onset, total number of days 
depressed over the past twelve months, number of diagnostic 
symptoms, distress (scale 0-100) or presence of work 
impairment (yes/no). Only the past-year frequency of 
depressive episodes showed a substantial effect, but due to 
small case number the associations were statistically not 
significant. Overall the results of the 4-day definition show 
a comparable validity to the 2-weeks definition, but for the 
definition of major depressive episodes distress and 
impairment would have to be included as in DSM-IV and 
ICD-10.
Application of the traditional 2-week diagnostic 
criterion for depression identified only some of the subjects 
treated for depression during the interview years (treatment 
prevalence rate 19.1%). This rate would be enhanced by 
broadening the duration criterion, e.g. by including 
depression lasting 4 or more days and even more by the 
inclusion of recurrent brief depression; this would identify a 
further 11% of treated subjects with 5+ diagnostic symptoms 
of depression, and increase the coverage by 50%.
Our study found a lifetime prevalence rate for treated 
depression of 34.1%; it should, however, be remembered 
that the probands were no more than 50 years old at the last 
interview and that with advancing age those rates can only 
increase. These high treatment rates far exceed the lifetime 
prevalence rates for major depressive episodes reported by 
the best epidemiological studies, which also included also 
non-treated subjects: 20% in the Nemesis study,10 21.9% in 
developed countries in the large WHO Mental Health 
Figure 2               ROC Curve
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ROC curve for general distress (0-100) as discriminator between 
treatment use and non-use in depressive syndrome DeSY (groups 1-4). 
The area above the diagonal represents the discriminatory power beyond 
pure chance
Surveys,11 22.3%12 and 24.2% in the NCS-R study based on 
SCID interviews.13 On the other hand, new estimates from a 
prospective birth cohort study by Moffitt of very high 
cumulative lifetime prevalence rates of 41.4% for DSM-IV 
MDE (up to the age of 32 only) are compatible with our 
findings.14 
As expected, treatment seeking was associated with 
female gender, age at onset, severity of depression measured 
by the number of criterial symptoms, length and frequency 
of episodes, suicidality, distress and work impairment. An 
early age at onset also correlated with delayed treatment in 
a study on bipolar disorders.15 Most of these variables are 
dimensional and support the views of Westen et al. on a 
dimensional classification of mood disorders.16 
ConCluSIon
To our knowledge, our study is the first systematically to 
test episode duration as a diagnostic criterion of depression. 
Its limitations include the relatively small sample and the 
restriction to an age cohort; its strength is that it is a 
prospective study spanning 30 years. The results evidently 
require replication before any changes to the current 
diagnostic concept which requires a minimum duration of 2 
weeks for major depressive episodes can proposed. We hope 
to have questioned the current definition and to stimulate 
further research for its improvement.
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